# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Verona Pharma (NASDAQ:VRNA) with a Buy and maintains $36 price...
Truist Securities analyst Joon Lee maintains Verona Pharma (NASDAQ:VRNA) with a Buy and raises the price target from $32 to ...
The FDA has approved Verona Pharma's Ohtuvayre (ensifentrine) as maintenance treatment of chronic obstructive pulmonary dis...
Canaccord Genuity analyst Edward Nash maintains Verona Pharma (NASDAQ:VRNA) with a Buy and maintains $35 price target.
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Verona Pharma (NASDAQ:VRNA) with a Buy and raises the price tar...
Ohtuvayre is the first inhaled product with a novel mechanism of action available for the maintenance treatment of COPD in more...